Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice
Conclusion. Patients who received atezolizumab plus bevacizumab as 1st-line therapy had better clinical outcome than those who received atezolizumab plus bevacizumab in later lines. The AFP response at 6 weeks could be a predictor of disease progression.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Avastin | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Hepatocellular Carcinoma | Investigational New Drugs | Japan Health | Liver Cancer